


 Cite this: *RSC Adv.*, 2018, **8**, 19402

 Received 2nd April 2018
 Accepted 9th May 2018

 DOI: 10.1039/c8ra02853b
rsc.li/rsc-advances

A convenient approach to difluoromethylated all-carbon quaternary centers *via* Ni(II)-catalyzed enantioselective Michael addition†

 Xuan Yu, Hui Bai, Dong Wang, Zhaoai Qin, Jia-Qi Li * and Bin Fu*

A Ni(II)-catalyzed enantioselective Michael addition of 2-acetyl azarenes with β -difluoromethyl substituted nitroalkenes was successfully realized, which afforded chiral CF_2H -containing compounds in good enantioselectivities (up to 93% ee). This protocol provides a new convenient approach to all-carbon quaternary stereogenic centers featuring a CF_2H group.

1 Introduction

The introduction of a CF_2H group into organic compounds modulates the metabolic ability, lipophilicity, hydrogen-bonding potency and bioactivity. Therefore, CF_2H -containing compounds have found widespread application in pharmaceuticals, agrochemicals and enzyme inhibitors.¹ During the past few years, methods for incorporating CF_2H into organic molecules have increased rapidly.² In the meantime, some successful examples on the synthesis of chiral CF_2H containing compounds have also been explored by means of catalytic asymmetric methods.³ In 2012, Zhou *et al.* reported that nitrogen-based Lewis bases could effectively activate difluoroenoxy silanes for a highly enantioselective synthesis of 3-difluoroalkyl 3-hydroxyoxindoles.^{4a} In 2015, Zhou's group employed a chiral secondary amine phosphoramido to catalyze efficiently the Mukaiyama–Michael addition of fluorinated enol silyl ethers to tetrasubstituted olefins, giving the oxindole products featuring an all-carbon quaternary stereocenter with either a difluoroalkyl or monofluoroalkyl group.^{4b} Subsequently they explored another Mukaiyama–Mannich reaction of fluorinated enol silyl ethers and cyclic *N*-sulfonyl ketimines by employing a hydroquinine-derived urea catalyst, affording benzosultam-based α -amino acid derivatives featuring a fluoroalkyl group.^{4c} In 2015, Mikami *et al.* reported that the highly enantioselective ene reactions with difluoropyruvate by using a dicationic palladium catalyst, giving α - CF_2H tertiary alcohols.⁵ In 2016, Jacobsen reported one exciting reaction of β -substituted styrenes with commercially available reagents (*m*-chloroperbenzoic acid and hydrogen fluoride pyridine) to

access a variety of products bearing difluoromethylated tertiary or quaternary stereocenters in the presence of simple chiral aryl iodide catalyst.⁶ Very recently, Hoveyda reported an efficient enantioselective addition of readily accessible Z - γ -substituted boronic acid pinacol ester compounds to fluoroalkyl-substituted ketones.⁷ Despite these notable advances in the introduction of CF_2H -moiety to chiral products, general and convenient methods remain limited.

It is well-known that the construction of all-carbon quaternary stereocenter is one challenging and even formidable topic in organic synthesis.⁸ In our recent research work, we have demonstrated that the construction of all-carbon quaternary stereocenters bearing a CF_3 -group or $-\text{CO}_2\text{R}$ could be realized by a Ni-bis(oxazoline) catalyst.⁹ Thus, we envision that whether the corresponding optical CF_2H -containing compounds could be achieved by the same catalytic system. To the best of our knowledge, only two successful examples involving chiral all-carbon quaternary center bearing a difluoroalkyl group have been reported by Zhou and Jacobsen.^{4b,6} Therefore, the development of efficient and concise method for the construction of all-carbon quaternary stereocenter featuring CF_2H group is of great significance and highly desirable for medicinal research. As a continuation of our ongoing research to explore efficient and economical asymmetric methodology,¹⁰ we herein report our recent findings on the addition of β -difluoromethyl nitroalkene with 2-acetyl azarenes.


2 Results and discussion

Based on our previous result,⁹ the complex of $\text{Ni}(\text{acac})_2\text{-Ph-BOX L1}$ was selected as the optimal catalyst. The reaction in the presence of 10 mol% of $\text{Ni}(\text{acac})_2$ and 11 mol% of L1 proceeded for 5 h in *iso*-propanol (*i*-PrOH) at room temperature, and afforded the addition product 3aa in 97% yield with 74% ee (Table 1, entry 1), lowering the reaction temperature to 0 °C and –20 °C led to an obvious improvement of the enantioselectivity (79% and 91% ee, respectively, entries 2–3), albeit along with

Department of Applied Chemistry, China Agricultural University, West Yuanmingyuan Rd. 2, Beijing 100193, People's Republic of China. E-mail: jiaqili@cau.edu.cn; fubinchem@cau.edu.cn

† Electronic supplementary information (ESI) available: Characterization and spectra. CCDC 1575270. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c8ra02853b



Table 1 Optimization of reaction conditions^a

Entry	Solvent	T	t (h)	Additive	Yield (%) ^b	ee (%) ^c
1	<i>i</i> -PrOH	rt	5	—	97	74
2	<i>i</i> -PrOH	0 °C	12	—	95	79
3	<i>i</i> -PrOH	-20 °C	60	—	92	91
4	MeOH	-20 °C	60	—	50	75
5	DCM	-20 °C	60	—	73	50
6	THF	-20 °C	60	—	77	70
7	<i>n</i> -Pentanol	-20 °C	60	—	61	80
8	EtOH	-20 °C	60	—	80	81
9	<i>i</i> -BuOH	-20 °C	60	—	95	83
10	<i>n</i> -BuOH	-20 °C	60	—	95	83
11	<i>i</i> -PrOH	rt	5	K ₂ CO ₃	83	2
12	<i>i</i> -PrOH	rt	5	CH ₃ ONa	72	21
13	<i>i</i> -PrOH	rt	5	4 Å	Trace	—

^a Unless otherwise noted, reactions were conducted with Ligand–metal (1.1 : 1, 10 mol%), **1a** (0.1 mmol), and **2a** (0.15 mmol) in solvent (1.5 mL). ^b Isolated yields. ^c Determined by chiral HPLC.

a longer reaction time. Comparing with the substrate of β -CF₃ substituted nitroalkene, this reaction exhibited more higher reactivity and somewhat lower enantioselectivity under the same reaction condition, which is presumably attributed to the low steric hindrance of $-\text{CF}_2\text{H}$ group. Moreover, other conditions including solvent and the additives were also investigated, but no more yields or ee values were obtained. Then the optimal condition was identified as the following: Ni(acac)₂–**L1** (10 mol%), *i*-PrOH, -20 °C.

Under the optimized reaction conditions, a variety of aromatic heterocycle of 2-acetyl azarenes were further investigated, as outlined in Table 2. For various azarenes containing a five-membered *N*-heterocycle, the reaction demonstrated good enantioselectivities and moderate reactivities (67–93% ee and 40–68% yields, entries 1–5). Among them 2-acetyl *N*-methyl 2-imidazolyl furnished the best catalytic results (93% ee, entry 3). Moreover, the substrates **3ag**–**3ai** containing six-membered *N*-heterocycles such as pyrazinyl, quinolinyl, 2-benzopyrazinyl and quinoxalinyl were also suitable reaction partners. A range of 71–80% ee values were obtained, although a relatively low reactivity was displayed in the case of 2-quinolinyl and 2-benzopyrazinyl groups (entries 7 and 8). In addition, when using the bulky 2-acetyl 6,7-dihydro-5*H*-quinolin-8-one as Michael donor, no reaction was observed (entry 9).

We next evaluated the scope of nitroalkenes. The results are summarized in Table 3. First, whatever an electron-rich or electron-deficient substituent at the *para*- or *meta*-position of the phenyl ring, the reaction proceeded smoothly to afford the

Table 2 The scope of azaarenes^a

Entry	1	Product	Yield (%) ^b	ee (%) ^c
1	2-Oxazolyl	3ab	58	71
2	2-Thiazolyl	3ac	48	81
3	<i>N</i> -methyl 2-imidazolyl	3ad	68	93
4	2-Benzoxazolyl	3ae	40	67
5	2-Benzothiazolyl	3af	48	75
6	2-Pyrazinyl	3ag	76	79
7	2-Quinolinyl	3ah	45	71
8	2-Benzopyrazinyl	3ai	38	80
9	6,7-Dihydro-5 <i>H</i> -quinolin-8-one	3aj	n.r. ^d	—

^a Unless otherwise noted, reactions were performed with **L1**–Ni(acac)₂ (1.1:1, 10 mol%), **1** (0.1 mmol), and **2a** (0.15 mmol) in *i*-PrOH (1.5 mL) at -20 °C for 60 h. ^b Yields of isolated products. ^c The ee value was determined by chiral HPLC analysis. ^d n.r. = no reaction.


ducts **3ba**–**3ga** in both good yields and enantioselectivities (74–86% yields and 71–83% ees, entries 1–6). These results demonstrated that the electronic properties of the substituent on the phenyl ring of the nitroalkene has little influence on the enantioselectivity and reactivity of the reaction. However an ortho-substituent on the phenyl ring of the nitroalkene has a remarkable detrimental effect on the reaction. No reaction took place with the substrate bearing an *ortho*-methoxy or *ortho*-chloro on the phenyl ring, which is probably attributed to the bulky steric hindrance at the *ortho*-position of the phenyl ring (entries 7 and 8). Unfortunately, for heptyl substituted nitroalkene the poor enantioselectivity was obtained (entry 9, 20% ee).

Table 3 The scope of nitroalkene^a

Entry	2	Product	Yield	ee (%) ^c
1	4-Methylphenyl	3ba	84	76
2	4-Methoxyphenyl	3ca	81	83
3	4-Chlorophenyl	3da	86	77
4	4-Trifluoromethylphenyl	3ea	74	81
5	3-Methoxyphenyl	3fa	76	71
6	3-Chlorophenyl	3ga	85	77
7	2-Methoxyphenyl	3ha	n.r. ^d	—
8	2-Chlorophenyl	3ia	n.r.	—
9	n-Heptyl	3ja	77	20

^a Unless otherwise noted, reactions were performed with **L1**–Ni(acac)₂ (1.1:1, 10 mol%), **1a** (0.1 mmol), and **2** (0.15 mmol) in *i*-PrOH (1.5 mL) at -20 °C for 60 h. ^b Yields of isolated products. ^c The ee value was determined by chiral HPLC analysis. ^d n.r. = no reaction.





Scheme 1 Scale up reaction.

ee), which is remarkably different from that of CF_3 -substituted nitroalkene. These results exhibited that, although only a fluoro-atom disparity between $-\text{CF}_2\text{H}$ and $-\text{CF}_3$ substituted nitroalkenes, the enantioselectivity showed obvious differences under the same catalytic system. Generally β -difluoromethyl substituted nitroalkenes gave somewhat lower enantioselectivity than corresponding β -trifluoromethyl substrates.

To further demonstrate the applicability of the current method in the synthesis of these types of molecules, a scale-up reaction was performed. Similar excellent yield and enantioselectivity were obtained (Scheme 1).

On the basis of X-ray diffraction analysis, the absolute configuration of compound **3ad** was determined to be (*S*) (Fig. 1),¹¹ and the configuration of other products was also assigned by analogy. Considering the observed stereochemistry, a plausible asymmetric induction model was proposed (Fig. 1). The coordination of BOX ligand **L1** to $\text{Ni}(\text{acac})_2$ gave rise to a Ni complex. Subsequently, an enolate was resulted by the interaction of 2-acetyl azaarene to this Ni complex. Meanwhile, nitroalkene was also activated through coordination to Ni. The *Si* face attack of the enolate was disfavoured due to the steric hindrance between the NO_2 group of nitroalkene and the phenyl substituent of the oxazoline ring, leading to the predominant *Re*-face addition.

However, in view of somewhat higher reactivity and lower enantioselectivity of difluoromethyl nitroalkenes in contrast to trifluoromethyl substrates under the same condition (Table 1, entries 1–3), it is believed that both electronic and steric effects of substituents on the nitroalkene have an impact on the

efficiency and enantioselectivity of the reaction, but the steric effect could play a much more important role, which is basically in agreement with our previous report.⁹

3 Conclusions

In summary, we have developed a $\text{Ni}(\text{II})$ -catalyzed asymmetric Michael addition reaction of β -difluoromethyl nitroalkene and 2-acetyl azaarene by employing an easily available catalyst. The reaction proceeded smoothly under mild conditions to afford the adducts in moderate to high yields and enantioselectivities (up to $>93\% \text{ ee}$). The reaction mechanism was discussed by comparison with that of $\beta\text{-CF}_3$ substituted nitroalkenes. These difluoromethylated compounds bearing an all-carbon quaternary stereocenter are interesting targets for medicinal research. Further applications of this methodology to the synthesis of functional chiral molecules are in progress in our laboratory.

4 Experimental section

4.1 General methods

The ^1H , ^{13}C , and ^{19}F NMR spectra were recorded on a Bruker Avance DPX300 instrument with TMS as internal standard. Mass spectra were obtained on Bruker APEX II FT-ICRMS mass spectrometer. Optical rotations were measured on a PerkinElmer 341 LC polarimeter. The enantiomeric excesses of (*R*)- and (*S*)-enantiomer were determined by Agilent 1260 HPLC analysis over a chiral column (Daicel Chiralcel OD-H, AD-H, AS-H or OJ-H; eluted with hexane/iso-propanol; UV detector). Solvents were purified and dried by standard procedures.

4.2 General procedure for the asymmetric Michael addition

Under nitrogen to a solution of ligand **L1** (0.011 mmol) in *i*-PrOH (1.5 mL) was added $\text{Ni}(\text{acac})_2$ (0.01 mmol). The reaction mixture was stirred for 1 h at room temperature before 2-acetyl azaarene **1** (0.1 mmol) was added. After stirring for 15 min. The resulting mixture was cooled to $-20\text{ }^\circ\text{C}$, and then a solution of nitroalkene **2** (0.15 mmol) was added. The reaction proceeded to completion at $-20\text{ }^\circ\text{C}$ (monitored by TLC). Subsequently, water (10 mL) was added and extracted with ethyl acetate (10 mL \times 3). The organic layer was combined, washed with brine, dried over Na_2SO_4 and concentrated. The residue was purified by flash column chromatography on silica gel (eluted with ethyl acetate/petroleum ether (1/10, v/v) to afford the desired product **3**.




Fig. 1 The proposed stereochemical model.

4.3 (S)-4,4-difluoro-3-(nitromethyl)-3-phenyl-1-(pyridin-2-yl)butan-1-one (3aa)

Yellow oil, 92% yield. $[\alpha]_D^{20} = -47.1$ ($c = 1.32$, CH_2Cl_2); 91% *ee*, determined by HPLC analysis [Daicel Chiralcel AD-H column, *n*-hexane/*i*-PrOH = 90 : 10, 1.0 mL min⁻¹, 254 nm; *t* (major) = 14.650 min, *t* (minor) = 13.159 min]; ¹H NMR (300 MHz, CDCl_3) δ 8.70 (d, $J = 4.2$ Hz, 1H), 7.96 (d, $J = 7.8$ Hz, 1H), 7.81 (dt, $J = 7.6, 1.1$ Hz, 1H), 7.50 (dd, $J = 4.9, 7.4$ Hz, 1H), 7.44–7.27 (m, 5H), 6.48 (t, $J = 56.0$ Hz, 1H), 5.38 (s, 2H), 4.37, 4.15 (ABq, $J = 18.0$ Hz, 2H). ¹³C NMR (75 MHz, CDCl_3) δ 197.66 (s), 152.48 (s), 148.73 (s), 136.73 (s), 134.31 (s), 128.56 (s), 128.06 (s), 127.43 (s), 126.54 (s), 121.51 (s), 116.13 (t, $J = 249.1$ Hz), 76.22 (s), 48.41 (t, $J = 19.0$ Hz), 37.04 (dd, $J = 4.2, 2.9$ Hz). ¹⁹F NMR (282 MHz, CDCl_3) δ -125.26 (q, $J = 280.3$ Hz). ESI-HRMS: Calcd for $\text{C}_{15}\text{H}_{16}\text{F}_2\text{N}_3\text{O}_3^+$ ($[\text{M} + \text{H}^+]$): 324.1154; found: 324.1149.

4.4 (S)-4,4-Difluoro-3-(nitromethyl)-1-(oxazol-2-yl)-3-phenylbutan-1-one (3ab)

Whitesolid, 58% yield. Mp. 96–110 °C. $[\alpha]_D^{20} = -17.2$ ($c = 0.56$, CH_2Cl_2); 75% *ee*, determined by HPLC analysis [Daicel Chiralcel AD-H column, *n*-hexane/*i*-PrOH = 95 : 5, 1.0 mL min⁻¹, 254 nm; *t* (major) = 37.009 min, *t* (minor) = 33.169 min]; ¹H NMR (300 MHz, CDCl_3) δ 7.82 (s, 1H), 7.36 (s, 6H), 6.44 (t, $J = 55.8$ Hz, 1H), 5.37, 5.31 (ABq, $J = 12.0$ Hz, 2H), 4.14, 4.02 (ABq, $J = 18.0$ Hz, 2H). ¹³C NMR (75 MHz, CDCl_3) δ 184.05 (s), 157.52 (s), 142.29 (s), 133.92 (s), 129.33 (s), 129.06 (s), 128.64 (s), 126.58 (s), 116.14 (t, $J = 249.6$ Hz), 76.13 (dd, $J = 5.6, 3.1$ Hz), 48.77 (t, $J = 19.1$ Hz), 38.75 (dd, $J = 4.5, 3.0$ Hz). ¹⁹F NMR (282 MHz, CDCl_3) δ -124.97 (q, $J = 281.3$ Hz). ESI-HRMS: Calcd for $\text{C}_{14}\text{H}_{13}\text{F}_2\text{N}_2\text{O}_4^+$ ($[\text{M} + \text{H}^+]$): 311.0838; found: 311.0835.

4.5 (S)-4,4-Difluoro-3-(nitromethyl)-3-phenyl-1-(thiazol-2-yl)butan-1-one (3ac)

Orange oil, 48% yield. $[\alpha]_D^{20} = -27.5$ ($c = 0.78$, CH_2Cl_2); 81% *ee*, determined by HPLC analysis [Daicel ChiralcelOD-H column, *n*-hexane/*i*-PrOH = 80 : 20, 1.0 mL min⁻¹, 254 nm; *t* (major) = 14.168 min, *t* (minor) = 12.471 min]; ¹H NMR (300 MHz, CDCl_3) δ 8.02 (d, $J = 2.8$ Hz, 1H), 7.70 (d, $J = 2.8$ Hz, 1H), 7.50–7.27 (m, 5H), 6.46 (t, $J = 55.8$ Hz, 1H), 5.39, 5.33 (ABq, $J = 12.0$ Hz, 2H), 4.25, 4.11 (ABq, $J = 18.0$ Hz, 2H). ¹³C NMR (75 MHz, CDCl_3) δ 189.86 (s), 166.12 (s), 144.90 (s), 134.18 (s), 128.97 (s), 128.53 (s), 127.15 (s), 126.66 (s), 116.23 (t, $J = 249.5$ Hz), 76.32 (dd, $J = 5.6, 3.0$ Hz), 48.76 (t, $J = 19.1$ Hz). ¹⁹F NMR (282 MHz, CDCl_3) δ -125.02 (q, $J = 280.9$ Hz). ESI-HRMS: Calcd for $\text{C}_{14}\text{H}_{13}\text{F}_2\text{N}_2\text{O}_3^+$ ($[\text{M} + \text{H}^+]$): 327.0609; found: 327.0604.

4.6 (S)-4,4-Difluoro-1-(1-methyl-1*H*-imidazol-2-yl)-3-(nitromethyl)-3-phenylbutan-1-one (3ad)

White solid, 68% yield. Mp. 72–74 °C, $[\alpha]_D^{20} = -110.4$ ($c = 2.14$, CH_2Cl_2); 93% *ee*, determined by HPLC analysis [Daicel Chiralcel AD-H column, *n*-hexane/*i*-PrOH = 90 : 10, 1.0 mL min⁻¹, 254 nm; *t* (major) = 21.285 min, *t* (minor) = 16.802 min]; ¹H NMR (300 MHz, CDCl_3) δ 7.37 (s, 5H), 7.15 (s, 1H), 7.03 (s, 1H), 6.43 (t, $J = 55.8$ Hz, 1H), 5.36 (s, 2H), 4.23, 4.03 (ABq, $J = 18.0$ Hz, 2H), 3.88 (s, 3H). ¹³C NMR (75 MHz, CDCl_3) δ 188.24 (s), 134.56

(s), 129.36 (s), 128.83 (s), 128.31 (s), 127.62 (s), 126.74 (s), 116.37 (t, $J = 249.3$ Hz), 76.46 (s), 48.74 (t, $J = 19.0$ Hz), 38.4 (dd, $J = 3.8, 3.0$ Hz), 36.03 (s). ¹⁹F NMR (282 MHz, CDCl_3) δ -125.21 (q, $J = 280.0$ Hz). ESI-HRMS: calcd for $\text{C}_{15}\text{H}_{16}\text{F}_2\text{N}_3\text{O}_3^+$ ($[\text{M} + \text{H}^+]$): 324.1154; found: 324.1149.

4.7 (S)-1-(benzo[*d*]oxazol-2-yl)-4,4-difluoro-3-(nitromethyl)-3-phenylbutan-1-one (3ae)

Orange oil, 40% yield. $[\alpha]_D^{20} = -18.9$ ($c = 0.68$, CH_2Cl_2); 67% *ee*, determined by HPLC analysis [Daicel ChiralcelOD-H column, *n*-hexane/*i*-PrOH = 80 : 20, 1.0 mL min⁻¹, 254 nm; *t* (major) = 24.226 min, *t* (minor) = 19.349 min]; ¹H NMR (300 MHz, CDCl_3) δ 7.92 (d, $J = 7.9$ Hz, 1H), 7.64 (d, $J = 8.0$ Hz, 1H), 7.52 (dt, $J = 15.0, 7.3$ Hz, 2H), 7.44–7.29 (m, 5H), 6.47 (t, $J = 55.7$ Hz, 1H), 5.40, 5.34 (ABq, $J = 12.0$ Hz, 2H), 4.29, 4.19 (ABq, $J = 18.0$ Hz, 2H). ¹³C NMR (75 MHz, CDCl_3) δ 185.96 (s), 156.69 (s), 150.92 (s), 140.32 (s), 135.32–130.96 (m), 129.10 (s), 129.01 (s), 128.69 (s), 126.60 (s), 126.02 (s), 122.44 (s), 116.15 (t, $J = 249.8$ Hz), 111.97 (s), 76.12 (dd, $J = 5.3, 2.8$ Hz), 48.85 (t, $J = 19.1$ Hz), 39.10 (dd, $J = 4.1, 2.7$ Hz). ¹⁹F NMR (282 MHz, CDCl_3) δ -124.81 (q, $J = 281.3$ Hz). ESI-HRMS: calcd for $\text{C}_{18}\text{H}_{17}\text{F}_2\text{N}_2\text{O}_4^+$ ($[\text{M} + \text{H}^+]$): 361.0994; found: 361.0990.

4.8 (S)-1-(benzo[*d*]thiazol-2-yl)-4,4-difluoro-3-(nitromethyl)-3-phenylbutan-1-one (3af)

Yellow oil, 48% yield. $[\alpha]_D^{20} = -13.8$ ($c = 0.45$, CH_2Cl_2); 75% *ee*, determined by HPLC analysis [Daicel ChiralcelOD-H column, *n*-hexane/*i*-PrOH = 90 : 10, 1.0 mL min⁻¹, 254 nm; *t* (major) = 26.581 min, *t* (minor) = 22.790 min]; ¹H NMR (300 MHz, CDCl_3) δ 8.22 (d, $J = 7.7$ Hz, 1H), 7.96 (d, $J = 7.4$ Hz, 1H), 7.68–7.49 (m, 2H), 7.47–7.26 (m, 5H), 6.48 (t, $J = 55.8$ Hz, 1H), 5.40, 5.35 (ABq, $J = 12.0$ Hz, 2H), 4.37, 4.23 (ABq, $J = 18.0$ Hz, 2H). ¹³C NMR (75 MHz, CDCl_3) δ 191.45 (s), 165.37 (s), 153.33 (s), 137.50 (s), 134.15 (s), 129.05 (s), 128.61 (s), 128.09 (s), 127.24 (s), 126.70 (s), 125.67 (s), 122.43 (s), 116.26 (t, $J = 249.6$ Hz), 76.35 (dd, $J = 5.8, 3.0$ Hz), 48.86 (t, $J = 19.1$ Hz), 38.34 (dd, $J = 4.3, 3.1$ Hz). ¹⁹F NMR (282 MHz, CDCl_3) δ -124.89 (q, $J = 280.9$ Hz). ESI-HRMS: calcd for $\text{C}_{18}\text{H}_{15}\text{F}_2\text{N}_2\text{O}_3\text{S}^+$ ($[\text{M} + \text{H}^+]$): 377.0766; found: 377.0763.

4.9 (S)-4,4-Difluoro-3-(nitromethyl)-3-phenyl-1-(pyrazin-2-yl)butan-1-one (3ag)

White solid, 76% yield. Mp. 104–106 °C, $[\alpha]_D^{20} = -40.1$ ($c = 1.24$, CH_2Cl_2); 79% *ee*, determined by HPLC analysis [Daicel ChiralcelAS-H column, *n*-hexane/*i*-PrOH = 80 : 20, 1.0 mL min⁻¹, 254 nm; *t* (major) = 23.778 min, *t* (minor) = 17.251 min]; ¹H NMR (300 MHz, CDCl_3) δ 9.17 (s, 1H), 8.79 (s, 1H), 8.67 (s, 1H), 7.36 (s, 5H), 6.46 (t, $J = 55.8$ Hz, 1H), 5.37 (s, 2H), 4.29, 4.13 (ABq, $J = 18.0$ Hz, 2H). ¹³C NMR (75 MHz, CDCl_3) δ 197.42 (s), 148.38 (s), 146.99 (s), 143.58 (s), 143.49 (s), 134.28 (s), 128.97 (s), 128.53 (s), 126.66 (s), 116.28 (t, $J = 249.4$ Hz), 76.36 (dd, $J = 5.8, 2.9$ Hz), 48.65 (t, $J = 19.1$ Hz), 37.38 (dd, $J = 4.5, 2.9$ Hz). ¹⁹F NMR (282 MHz, CDCl_3) δ -125.13 (q, $J = 280.9$ Hz). ESI-HRMS: calcd for $\text{C}_{15}\text{H}_{14}\text{F}_2\text{N}_3\text{O}_3^+$ ($[\text{M} + \text{H}^+]$): 322.0998; found: 322.0995.



4.10 (S)-4,4-Difluoro-3-(nitromethyl)-3-phenyl-1-(quinolin-2-yl)butan-1-one (3ah)

Orange solid, 45% yield. Mp. 85–92 °C, $[\alpha]_D^{20} = -64.4$ ($c = 1.46$, CH_2Cl_2); 70% *ee*, determined by HPLC analysis [Daicel Chiralcel AD-H column, *n*-hexane/*i*-PrOH = 90 : 10, 1.0 mL min⁻¹, 254 nm; *t* (major) = 15.068 min, *t* (minor) = 13.060 min]; ¹H NMR (300 MHz, CDCl_3) δ 8.26 (dd, *J* = 8.3, 2.6 Hz, 2H), 8.04 (d, *J* = 8.5 Hz, 1H), 7.91–7.86 (m, 1H), 7.82 (ddd, *J* = 8.5, 6.9, 1.5 Hz, 1H), 7.68 (ddd, *J* = 8.1, 7.0, 1.2 Hz, 1H), 7.50–7.29 (m, 5H), 6.55 (t, *J* = 56.0 Hz, 1H), 5.43 (s, 2H), 4.57, 4.32 (ABq, *J* = 18.0 Hz, 2H). ¹³C NMR (75 MHz, CDCl_3) δ 198.33 (s), 152.38 (s), 147.08 (s), 137.17 (s), 134.71 (s), 130.70 (s), 130.26 (s), 129.85 (s), 128.97 (s), 128.90 (s), 128.38 (s), 127.66 (s), 126.91 (s), δ 116.52 (t, *J* = 249.1 Hz), 117.86 (s), 76.75 (dd, *J* = 6.0, 3.1 Hz), 48.88 (t, *J* = 19.0 Hz), 37.15 (dd, *J* = 4.3, 2.8 Hz). ¹⁹F NMR (282 MHz, CDCl_3) δ –125.24 (q, *J* = 280.2 Hz). ESI-HRMS: calcd for $\text{C}_{20}\text{H}_{17}\text{F}_2\text{N}_2\text{O}_3^+$ ($[\text{M} + \text{H}^+]$): 371.1202; found: 371.1198.

4.11 (S)-4,4-difluoro-3-(nitromethyl)-3-phenyl-1-(quinoxalin-2-yl)butan-1-one (3ai)

Yellow solid, 38% yield. Mp. 108–114 °C, $[\alpha]_D^{20} = -35.1$ ($c = 0.42$, CH_2Cl_2); 80% *ee*, determined by HPLC analysis [Daicel ChiralcelAD-H column, *n*-hexane/*i*-PrOH = 90 : 10, 1.0 mL min⁻¹, 254 nm; *t* (major) = 15.516 min, *t* (minor) = 17.459 min]; ¹H NMR (300 MHz, CDCl_3) δ 9.42 (s, 1H), 8.23 (d, *J* = 20.5 Hz, 2H), 7.92 (s, 2H), 7.40 (s, 5H), 6.53 (t, *J* = 55.4 Hz, 1H), 5.42 (s, 2H), 4.48, 4.29 (ABq, *J* = 18.0 Hz, 2H). ¹³C NMR (75 MHz, CDCl_3) δ 197.69 (s), 145.81 (s), 144.24 (s), 142.82 (s), 140.82 (s), 134.39 (s), 132.67 (s), 131.03 (s), 130.56 (s), 129.49 (s), 129.03 (s), 128.57 (s), 126.75 (s), 116.39 (t, *J* = 249.3 Hz), 76.53 (m), 48.78 (t, *J* = 19.1 Hz), 37.19 (dd, *J* = 4.2, 3.0 Hz). ¹⁹F NMR (282 MHz, CDCl_3) δ –125.09 (q, *J* = 280.8 Hz). ESI-HRMS: calcd for $\text{C}_{19}\text{H}_{16}\text{F}_2\text{N}_3\text{O}_3^+$ ($[\text{M} + \text{H}^+]$): 372.1154; found: 372.1150.

4.12 (S)-4,4-difluoro-3-(nitromethyl)-1-(pyridin-2-yl)-3-(*p*-tolyl)butan-1-one (3ba)

Colorless oil, 84% yield. $[\alpha]_D^{20} = -53.1$ ($c = 1.26$, CH_2Cl_2); 76% *ee*, determined by HPLC analysis [Daicel Chiralcel OD-H column, *n*-hexane/*i*-PrOH = 90 : 10, 1.0 mL min⁻¹, 254 nm; *t* (major) = 12.882 min, *t* (minor) = 14.746 min]; ¹H NMR (300 MHz, CDCl_3) δ 8.70 (d, *J* = 4.2 Hz, 1H), 7.97 (d, *J* = 7.8 Hz, 1H), 7.82 (dt, *J* = 7.6, 1.4 Hz, 1H), 7.50 (dd, *J* = 7.6, 4.9 Hz, 1H), 7.21 (dd, *J* = 27.4, 8.1 Hz, 4H), 6.45 (t, *J* = 56.1 Hz, 1H), 5.36 (s, 2H), 4.14, 4.34 (ABq, *J* = 18.0 Hz, 2H), 2.31 (s, 3H). ¹³C NMR (75 MHz, CDCl_3) δ 198.02 (s), 152.85 (s), 149.00 (s), 138.18 (s), 136.99 (s), 131.85–131.34 (m), 129.58 (s), 127.65 (s), 126.67 (d, *J* = 1.4 Hz), 121.80 (s), 116.47 (t, *J* = 249.1 Hz), 76.72–76.61 (m), 48.46 (t, *J* = 18.9 Hz), 37.31 (dd, *J* = 4.5, 2.9 Hz), 20.85 (s). ¹⁹F NMR (282 MHz, CDCl_3) δ –125.36 (q, *J* = 280.0 Hz). ESI-HRMS: calcd for $\text{C}_{17}\text{H}_{17}\text{F}_2\text{N}_2\text{O}_3^+$ ($[\text{M} + \text{H}^+]$): 335.1202; found: 335.1197.

4.13 (S)-4,4-Difluoro-3-(4-methoxyphenyl)-3-(nitromethyl)-1-(pyridin-2-yl)butan-1-one (3ca)

Yellow oil, 81% yield. $[\alpha]_D^{20} = -68.9$ ($c = 1.44$, CH_2Cl_2); 84% *ee*, determined by HPLC analysis [Daicel Chiralcel AS-H column, *n*-

hexane/*i*-PrOH = 90 : 10, 1.0 mL min⁻¹, 254 nm; *t* (major) = 33.111 min, *t* (minor) = 31.418 min]; ¹H NMR (300 MHz, CDCl_3) δ 8.70 (d, *J* = 4.4 Hz, 1H), 7.97 (d, *J* = 7.8 Hz, 1H), 7.81 (dt, *J* = 7.8, 1.0 Hz, 1H), 7.50 (dd, *J* = 6.9, 5.1 Hz, 1H), 7.28 (t, *J* = 7.7 Hz, 2H), 6.87 (d, *J* = 8.8 Hz, 2H), 6.45 (t, *J* = 56.2 Hz, 1H), 5.34 (s, 2H), 4.34, 4.13 (ABq, *J* = 18.0 Hz, 2H), 3.76 (s, 3H). ¹³C NMR (75 MHz, CDCl_3) δ 198.07 (s), 159.31 (s), 152.82 (s), 148.99 (s), 136.99 (s), 128.08 (s), 127.66 (s), 126.24 (s), 121.77 (s), δ 116.44 (t, *J* = 248.8 Hz), 114.19 (s), 76.74–76.57 (m), 55.12 (s), 48.22 (t, *J* = 19.0 Hz), 38.94–35.93 (m). ¹⁹F NMR (282 MHz, CDCl_3) δ –125.42 (q, *J* = 280.0 Hz). ESI-HRMS: calcd for $\text{C}_{17}\text{H}_{17}\text{F}_2\text{N}_2\text{O}_4^+$ ($[\text{M} + \text{H}^+]$): 351.1151; found: 351.1147.

4.14 (S)-3-(4-chlorophenyl)-4,4-difluoro-3-(nitromethyl)-1-(pyridin-2-yl)butan-1-one (3da)

Colorless oil, 86% yield. $[\alpha]_D^{20} = -55.8$ ($c = 1.13$, CH_2Cl_2); 77% *ee*, determined by HPLC analysis [Daicel ChiralcelAS-H column, *n*-hexane/*i*-PrOH = 80 : 20, 1.0 mL min⁻¹, 254 nm; *t* (major) = 16.024 min, *t* (minor) = 13.599 min]; ¹H NMR (300 MHz, CDCl_3) δ 8.70 (d, *J* = 4.6 Hz, 1H), 7.96 (d, *J* = 7.8 Hz, 1H), 7.83 (dt, *J* = 7.9, 1.1 Hz, 1H), 7.51 (dd, *J* = 7.4, 4.8 Hz, 1H), 7.45–7.27 (m, 4H), 6.47 (t, *J* = 56.0 Hz, 1H), 5.37, 5.32 (ABq, *J* = 12.0 Hz, 2H), 4.35, 4.11 (ABq, *J* = 18.0 Hz, 2H). ¹³C NMR (75 MHz, CDCl_3) δ 197.78 (s), 152.63 (s), 149.05 (s), 137.07 (s), 134.55 (s), 133.06 (s), 129.00 (s), 128.40 (s), 127.83 (s), 121.83 (s), 116.00 (t, *J* = 249.2 Hz), 76.41 (dd, *J* = 5.9, 3.1 Hz), 48.42 (t, *J* = 19.1 Hz), 37.37 (dd, *J* = 4.4, 2.7 Hz). ¹⁹F NMR (282 MHz, CDCl_3) δ –125.51 (q, *J* = 281.5 Hz). ESI-HRMS: calcd for $\text{C}_{16}\text{H}_{14}\text{ClF}_2\text{N}_2\text{O}_3^+$ ($[\text{M} + \text{H}^+]$): 355.0656; found: 355.0653.

4.15 (S)-4,4-Difluoro-3-(nitromethyl)-1-(pyridin-2-yl)-3-(4-(trifluoromethyl)phenyl)butan-1-one (3ea)

White solid, 74% yield. Mp. 82–83 °C, $[\alpha]_D^{20} = -49.5$ ($c = 1.50$, CH_2Cl_2); 81% *ee*, determined by HPLC analysis [Daicel ChiralcelAS-H column, *n*-hexane/*i*-PrOH = 80 : 20, 1.0 mL min⁻¹, 254 nm; *t* (major) = 10.203 min, *t* (minor) = 9.375 min]; ¹H NMR (300 MHz, CDCl_3) δ 8.71 (s, 1H), 7.97 (s, 1H), 7.85 (s, 1H), 7.64 (s, 2H), 7.53 (s, 3H), 6.52 (t, *J* = 56.3 Hz, 1H), 5.40 (s, 2H), 4.41, 4.15 (ABq, *J* = 18.0 Hz, 2H). ¹³C NMR (75 MHz, CDCl_3) δ 197.68 (s), 152.56 (s), 149.10 (s), 138.67 (s), 137.12 (s), 130.60 (q, *J* = 32.9 Hz), 127.92 (s), 127.55 (s), 125.73 (q, *J* = 3.6 Hz), 125.52 (s), 121.87 (s), 115.90 (t, *J* = 249.4 Hz), 76.33 (dd, *J* = 5.8, 3.2 Hz), 48.76 (t, *J* = 19.1 Hz), 37.48 (dd, *J* = 4.4, 2.7 Hz). ¹⁹F NMR (282 MHz, CDCl_3) δ –62.88 (s), –125.52 (q, *J* = 282.3 Hz). ESI-HRMS: calcd for $\text{C}_{17}\text{H}_{14}\text{F}_3\text{N}_2\text{O}_3^+$ ($[\text{M} + \text{H}^+]$): 389.0919; found: 389.0915.

4.16 (S)-4,4-Difluoro-3-(3-methoxyphenyl)-3-(nitromethyl)-1-(pyridin-2-yl)butan-1-one (3fa)

Colorless oil, 76% yield. $[\alpha]_D^{20} = -46.1$ ($c = 1.16$, CH_2Cl_2); 71% *ee*, determined by HPLC analysis [Daicel Chiralcel OD-H column, *n*-hexane/*i*-PrOH = 90 : 10, 1.0 mL min⁻¹, 254 nm; *t* (major) = 27.608 min, *t* (minor) = 20.249 min]; ¹H NMR (300 MHz, CDCl_3) δ 8.70 (d, *J* = 4.4 Hz, 1H), 7.96 (d, *J* = 7.9 Hz, 1H), 7.81 (dt, *J* = 7.7, 1.6 Hz, 1H), 7.56–7.42 (m, 1H), 7.27 (dd, *J* = 10.0, 6.4 Hz, 1H), 6.94 (d, *J* = 7.6 Hz, 2H), 6.85 (dd, *J* = 7.5, 1.8 Hz, 1H), 6.47 (t,



$J = 56.0$ Hz, 1H), 5.36 (s, 2H), 4.34, 4.14 (ABq, $J = 18.0$ Hz, 2H), 3.74 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 197.94 (s), 159.78 (s), 152.79 (s), 149.00 (s), 137.00 (s), 136.25 (s), 129.81 (s), 127.67 (s), 121.80 (s), 119.03 (s), δ 116.44 (t, $J = 249.3$ Hz), 113.81 (s), 112.97 (s), 76.62 (m), 55.16 (s), 48.74 (t, $J = 18.9$ Hz), 37.33 (dd, $J = 4.4$, 2.8 Hz). ^{19}F NMR (282 MHz, CDCl_3) δ -125.10 (q, $J = 280.0$ Hz). ESI-HRMS: calcd for $\text{C}_{17}\text{H}_{17}\text{F}_2\text{N}_2\text{O}_4^+ ([\text{M} + \text{H}^+])$: 351.1151; found: 351.1148.

4.17 (S)-3-(3-chlorophenyl)-4, 4-difluoro-3-(nitromethyl)-1-(pyridin-2-yl)butan-1-one (3ga)

Colorless oil, 85% yield. $[\alpha]_D^{20} = -51.0$ ($c = 1.24$, CH_2Cl_2); 78% ee, determined by HPLC analysis [Daicel Chiralcel OD-H column, *n*-hexane/*i*-PrOH = 90 : 10, 1.0 mL min⁻¹, 254 nm; *t* (major) = 16.516 min, *t* (minor) = 14.898 min]; ^1H NMR (300 MHz, CDCl_3) δ 8.71 (d, $J = 4.5$ Hz, 1H), 7.97 (d, $J = 7.8$ Hz, 1H), 7.83 (dt, $J = 7.8$, 1.6 Hz, 1H), 7.51 (dd, $J = 6.8$, 5.2 Hz, 1H), 7.39 (s, 1H), 7.35-7.23 (m, 3H), 6.48 (t, $J = 55.9$ Hz, 1H), 5.38, 5.33 (ABq, $J = 12.0$ Hz, 2H), 4.34, 4.11 (ABq, $J = 18.0$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3) δ 197.70 (s), 152.61 (s), 149.05 (s), 137.06 (s), 136.67 (s), 134.91 (s), 129.96 (s), 128.63 (s), 127.82 (s), 127.39 (s), 125.15 (s), 121.83 (s), 115.96 (t, $J = 249.4$ Hz), 76.29 (dd, $J = 5.8$, 3.1 Hz), 48.58 (t, $J = 19.2$ Hz), 37.34 (dd, $J = 4.2$, 2.9 Hz). ^{19}F NMR (282 MHz, CDCl_3) δ -125.41 (q, $J = 281.6$ Hz). ESI-HRMS: calcd for $\text{C}_{16}\text{H}_{14}\text{ClF}_2\text{N}_2\text{O}_3^+ ([\text{M} + \text{H}^+])$: 355.0656; found: 355.0654.

4.18 (R)-3-(difluoromethyl)-3-(nitromethyl)-1-(pyridin-2-yl)decan-1-one (3ja)

Colorless oil, 77% yield. $[\alpha]_D^{20} = +2.8$ ($c = 1.62$, CH_2Cl_2); 20% ee, determined by HPLC analysis [Daicel Chiralcel OJ-H column, *n*-hexane/*i*-PrOH = 95 : 5, 1.0 mL min⁻¹, 254 nm; *t* (major) = 10.455 min, *t* (minor) = 10.999 min]; ^1H NMR (300 MHz, CDCl_3) δ 8.68 (d, $J = 4.2$ Hz, 1H), 8.04 (d, $J = 7.8$ Hz, 1H), 7.87 (dt, $J = 7.7$, 1.4 Hz, 1H), 7.51 (dd, $J = 7.3$, 4.9 Hz, 1H), 6.24 (t, $J = 55.9$ Hz, 1H), 4.92, 4.86 (ABq, $J = 12.0$ Hz, 2H), 3.67 (s, 2H), 1.75 (dd, $J = 15.2$, 8.0 Hz, 2H), 1.53-1.33 (m, 2H), 1.26 (s, 8H), 0.86 (t, $J = 6.7$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 198.79 (s), 152.96 (s), 148.95 (s), 137.00 (s), 127.58 (s), 121.70 (s), 117.43 (t, $J = 247.9$ Hz), 76.25 (t, $J = 4.2$ Hz), 44.79 (t, $J = 18.6$ Hz), 36.33 (t, $J = 3.6$ Hz), 31.62 (s), 31.07 (t, $J = 2.7$ Hz), 30.00 (s), 28.81 (s), 23.42 (s), 22.50 (s), 13.96 (s). ^{19}F NMR (282 MHz, CDCl_3) δ -127.79 (q, $J = 282.0$ Hz). ESI-HRMS: calcd for $\text{C}_{17}\text{H}_{25}\text{F}_2\text{N}_2\text{O}_3^+ ([\text{M} + \text{H}^+])$: 343.1828; found: 343.1824.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The financial support from NSFC program (21172255) and the Ministry of Science and Technology of China (No. 2015BAK45B01, 2009BAK61B04) is appreciated.

References

- (a) J. Wang, M. Sánchez-Roselló, J. L. Aceña, C. del Pozo, A. E. Sorochinsky, S. Fustero, V. A. Soloshonok and H. Liu, *Chem. Rev.*, 2014, **114**, 2432-2506; (b) E. P. Gillis, K. J. Eastman, M. D. Hill, D. J. Donnelly and N. A. Meanwell, *J. Med. Chem.*, 2015, **58**, 8315-8359; (c) B. J. Elisabeth, M. M. M. Woodhead, Patent WO 2007096576, 2007; (d) L. David, D. Robert, S. Dean, A. Alexander, Patent WO 2007111904, 2007; (e) G. W. Rewcastle, S. A. Gamage, J. U. Flanagan, R. Frederick, W. A. Denny, B. C. Baguley, P. Kestell, R. Singh, J. D. Kendall, E. S. Marshall, C. L. Lill, W.-J. Lee, S. Kolekar, C. M. Buchanan, S. M. F. Jamieson and P. R. Shepherd, *J. Med. Chem.*, 2011, **54**, 7105-7126; (f) Y. Zafrani, D. Yeffet, G. Sod-Moriah, A. Berliner, D. Amir, D. Marciano, E. Gershonov and S. Saphier, *J. Med. Chem.*, 2017, **60**, 797-804; (g) N. A. Meanwell, *J. Med. Chem.*, 2011, **54**, 2529-2591.
- For selected literatures on the introduction of CF_2H -moiety to organic compounds: (a) J. Hu, W. Zhang and F. Wang, *Chem. Commun.*, 2009, 7465-7478; (b) J. Liu and J. Hu, *Chem.-Eur. J.*, 2010, **16**, 11443-11454; (c) T. Liang, C. N. Neumann and T. Ritter, *Angew. Chem. Int. Ed.*, 2013, **52**, 8214-8264; (d) A. G. O'Brien, A. Maruyama, Y. Inokuma, M. Fujita, P. S. Baran and D. G. Blackmond, *Angew. Chem. Int. Ed.*, 2014, **53**, 11868-11871; (e) C. Ni, M. Hu and J. Hu, *Chem. Rev.*, 2015, **115**, 765-825; (f) X.-J. Tang and W. R. Dolbier Jr, *Angew. Chem. Int. Ed.*, 2015, **54**, 4246-4249; (g) C. S. Thomoson, X.-J. Tang and W. R. Dolbier Jr, *J. Org. Chem.*, 2015, **80**, 1264-1268; (h) X.-J. Tang, Z. Zhang and W. R. Dolbier Jr, *Chem.-Eur. J.*, 2015, **21**, 18961-18965; (i) Z. He, P. Tan, C. Ni and J. Hu, *Org. Lett.*, 2015, **17**, 1838-1841; (j) Y. Arai, R. Tomita, G. Ando, T. Koike and M. Akita, *Chem.-Eur. J.*, 2016, **22**, 1262-1265; (k) I. G. Molnár and R. Gilmour, *J. Am. Chem. Soc.*, 2016, **138**, 5004-5007; (l) A. Tarui, S. Shinohara, K. Sato, M. Omote and A. Ando, *Org. Lett.*, 2016, **18**, 1128-1131.
- (a) W. Kashikura, K. Mori and T. Akiyama, *Org. Lett.*, 2011, **13**, 1860-1863; (b) Y.-L. Liu, J.-S. Yu and J. Zhou, *Asian J. Org. Chem.*, 2013, **2**, 194-206; (c) J.-H. Lin and J.-C. Xiao, *Tetrahedron Lett.*, 2014, **55**, 6147-6155.
- (a) Y.-L. Liu and J. Zhou, *Chem. Commun.*, 2012, 1919-1921; (b) J.-S. Yu, F.-M. Liao, W.-M. Gao, K. Liao, R.-L. Zuo and J. Zhou, *Angew. Chem. Int. Ed.*, 2015, **54**, 7381-7385; (c) J.-S. Yu and J. Zhou, *Org. Chem. Front.*, 2016, **3**, 298-303.
- K. Aikawa, S. Yoshida, D. Kondo, Y. Asai and K. Mikami, *Org. Lett.*, 2015, **17**, 5108-5111.
- S. M. Banik, J. W. Medley and E. N. Jacobsen, *Science*, 2016, **353**(6294), 51-54.
- F. W. van der Mei, C.-M. Qin, R. J. Morrison and A. H. Hoveyda, *J. Am. Chem. Soc.*, 2017, **139**, 9053-9065.
- (a) J. T. Mohr, M. R. Krout and B. M. Stoltz, *Nature*, 2008, **455**, 323-332; (b) M. Bella and T. Gasperi, *Synthesis*, 2009, **2009**, 1583-1614; (c) Y.-L. Liu, X. Wang, Y.-L. Zhao, F. Zhu,



X.-P. Zeng, L. Chen, C.-H. Wang, X.-L. Zhao and J. Zhou, *Angew. Chem., Int. Ed.*, 2013, **52**, 13735–13739; (d) X.-P. Yin, X.-P. Zeng, Y.-L. Liu, F.-M. Liao, J.-S. Yu, F. Zhou and J. Zhou, *Angew. Chem., Int. Ed.*, 2014, **53**, 13740–13745; (e) K. W. Quasdorff and L. E. Overman, *Nature*, 2014, **516**, 181–191.

9 (a) X.-H. Hou, H.-L. Ma, Z.-H. Zhang, L. Xie, Z.-H. Qin and B. Fu, *Chem. Commun.*, 2016, **52**, 1470–1473; (b) H.-L. Ma, L. Xie, Z.-H. Zhang, L.-G. Wu, B. Fu and Z.-H. Qin, *J. Org. Chem.*, 2017, **82**, 7353–7362.

10 (a) L. Liu, Q.-Y. Zhao, F.-P. Du, H. L. Chen, Z.-H. Qin and B. Fu, *Tetrahedron: Asymmetry*, 2011, **22**, 1874–1878; (b) H. L. Ma, L. Xie, Z.-H. Zhang, J.-Q. Li, Z.-H. Qin and B. Fu, *Adv. Synth. Catal.*, 2016, **358**, 1011–1016; (c) L. Xie, X. Yu, J.-Q. Li, Z.-H. Zhang, Z.-H. Qin and B. Fu, *Eur. J. Org. Chem.*, 2017, **2017**, 657–661; (d) L. Xie, H. Bai, J.-Q. Li, X. Yu, Z.-H. Zhang and B. Fu, *Tetrahedron*, 2017, **73**, 2923–2930; (e) L. Xie, H.-L. Ma, J.-Q. Li, X. Yu, Z.-H. Qin and B. Fu, *Org. Chem. Front.*, 2017, **4**, 1858–1862.

11 Crystallographic Data Centre as supplementary publication number CCDC 1575270. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK. Fax: t44 1223 336033 or e-mail: deposit@ccdc.cam.ac.uk.

